FDA Links Viberzi to Pancreatitis and Death Risk
The FDA approved Viberzi in May 2015 for the treatment of irritable bowel syndrome where diarrhea is the primary symptom. Since then, there have been at least 120 reports of pancreatitis or death.
Elizabeth Bradley / September 27, 2017
FDA: Viberzi Linked to Pancreatitis, Death Risk
The anti-diarrhea drug Viberzi has been linked to 120 reports of severe pancreas inflammation (pancreatitis) and death. These life-threatening side effects are more likely in people without gallbladders.
Daily Hornet / March 16, 2017